Abstract:Purpose: A prospective Phase I/II dose escalation study was conducted to determine the maximum tolerated dose (MTD) in three-dimensional conformal radiation therapy (3D-CRT) for non-small-cell lung cancer (NSCLC).Methods and Materials: MTD would be reached via a dose escalation study. After 42 Gy/21 fractions, 4.2 weeks by conventional fractionated irradiation through anteroposterior/posteroanterior fields, the 3D-CRT technique was used as boost. The planned total dose escalation depended on lung volume irradiated. According to the percentage of lung volume receiving >20 Gy, the patients were divided into three subgroups (i.e., <25%, 25%-37%, and >37%). The scheduled dose escalation began with 69 Gy and continued to 78 Gy. The boost doses were delivered at 3 Gy per fraction, once per day, five fractions per week. Each dose level includes 5 patients. Besides radiotherapy, all patients received neoadjuvant and adjuvant chemotherapy with MVP regimen (Mitomycin, Vindesine, cis-platium). The criterion for stopping further dose escalation was greater than or equal to20% of patients with greater than or equal toRTOG Grade 3 radiation pneumonitis.Results: Between June 1999 and February 2001, 50 patients had been enrolled in this study, including 4 with Stage II disease, 31 with Stage IIIa disease, and 15 with Stage IIIb disease. The dose escalation plan has been completed. All subgroups reached the highest predetermined dose levels (i.e., 78 Gy for the <25% subgroup, 78 Gy for the 25-37% subgroup, and 75 Gy for the >37% subgroup). Although none of the subgroups developed more than 20% of greater than or equal toGrade 3 acute pneumonitis, dose escalation was terminated because long-term follow-up was needed to observe late complications. Median follow-up time (NUT) for the entire group was 18 months (6-37 months). The most common acute complication was esophagitis in 56% of patients with RTOG Grade 1-2, and in 4% with Grade 3. Acute radiation pneumonitis developed in 36% of patients with RTOG Grade 1-2. Only 1 patient had Grade 3 pneumonitis, which was in the 25-37% subgroup at 75 Gy. The hematopoietic toxicity appeared in 58% of patients with Grade 1-2, and 8% with Grade 3. As to late complications, only 30% of patients developed pulmonary fibrosis of RTOG Grade 1-2. The median survival time for the entire group was 18 months. Two-year overall survival, locoregional progression-free rate, and distant metastasis rate were 44%, 40%, and 41%, respectively.Conclusion: Although MFT was 18 months, it had not yet been declared because a longer follow-up was needed to observe the late complications. The 2-year overall survival of 44% was very encouraging and implied that 3D-CRT combined with chemotherapy would improve the outcome for locally advanced NSCLC. (C) 2003 Elsevier Inc.

Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective phase I-II clinical trial.

Study of Late Course Three Dimensional-Conformal Radiotherapy Combined with Chemotherapy for 29 Cases with Recurrent Rectal Cancer.

Three-dimensional Conformal Radiotherapy Combined with FOLFOX4 Chemotherapy for Unresectable Recurrent Rectal Cancer

Three-Dimensional Conformal Radiation Therapy For Non-Small-Cell Lung Cancer: A Phase I/Ii Dose Escalation Clinical Trial

Three Dimensional Conformal Radiotherapy for Locally Advanced Rectal Cancer and Recurrent Rectal Cancer

Re-irradiation Using 3-Dimensional Conformal Radiation Therapy for Definitive Treatment of 140 Cases of Locally Recurrent Nasopharyngeal Carcinoma

Three-dimensional conformal radiation therapy for squamous cell carcinoma of the esophagus: a prospective phase I/II study.

Phase I/II Trial Evaluating Carbon-Ion Radiotherapy for Salvage Treatment of Locally Recurrent Nasopharyngeal Carcinoma

A prospective, multicenter, phase II clinical study of three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small-cell lung cancer-PPRA-RTOG003

Three Dimensional-conformal Radiotherapy Combined Concurrent Chemotherapy with Vinorelbine and Cisplatin for Stage Ⅲ Non-small Cell Lung Cancer

Clinical Study on the Effect of Hypofractionated Three -Dimensional Conformal Radiation Therapy in the Treatment of Non -Small Cell Lung Cancer

Three-Dimensional Conformal Radiation Therapy in the Salvage of 212 Locally Recurrent Nasopharyngeal Carcinoma Cases

Three-Dimensional Radiation Therapy to the Primary Tumor with Concurrent Chemotherapy in Patients with Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study from PPRA-RTOG, China

Study of Three-Dimensional Conformal Radiotherapy Combined with Concurrent Pemetrexed Chemotherapy and Erlotinib Maintenance in Treatment of Non-Squamous Cell Carcinoma of Locally Advanced Lung Cancer

Clinical Study of Late-Course Three-Dimensional Conformal Radiotherapy for Esophageal Carcinoma

Three-dimensional Conformal Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma

Long-Term Outcomes of Three-Dimensional Conformal Radiation Therapy Without Chemotherapy for Esophageal Squamous Cell Carcinoma: A Final Report of a Phase 2 Study

Three-Dimensional Conformal Radiotherapy for Unresectable or Post-Operative Residual Biliary Tract Carcinoma

Short-term Efficacy of Three-dimensional Conformal Radiotherapy Combined with Chemotherapy in the Treatment of Local Recurrence in Advanced Non-small Cell Lung Cancer

Dose Escalation of Three-dimensional Conformal Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma: A Prospective Randomised Study

A Phase II Trial of Accelerated Hypofractionated Three-Dimensional Conformal Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer